FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Struthers Richard Scott	2. Date of Event Requiring Statement (Month/Day/Year) 07/17/2018 3. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX]									
(Last) (First) (Middle) C/O CRINETICS PHARMACEUTICALS, INC.			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner V Officer (give title Other (specify)			5. If Amendment, Date of Original Filed (Month/Day/Year)				
10222 BARNES CANYON ROAD, BLDG. #2			X Officer (give title Other (specify below) See Remarks			Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) SAN DIEGO CA 92121						Form filed by Reporting Pe	y More than One erson			
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)			. Nature of Indirect Beneficial Ownership Instr. 5)				
Common Stock			1,215,805	D						
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	or Indirect (I) (Instr. 5)				
Stock Option (right to buy)	(1)	03/16/2028	Common Stock	182,370	1.91	D				
Stock Option (right to buy)	(2)	05/24/2028	Common Stock	364,741	9.28	D				

Explanation of Responses:

1. 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.

Remarks:

President and Chief Executive Officer

<u>/s/ R. Scott Struthers</u> <u>07/17/2018</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2. 1/48}th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date; provided, however, that one-half of the shares subject to the option are subject to the further condition that they may not be exercised until the occurrence of the Issuer's initial public offering and, in the event the Issuer's initial public offering does not occur prior to the first anniversary of May 25, 2018, such portion of the stock options shall be automatically forfeited. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.